About Veru Inc.
https://www.verupharma.comVeru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.
CEO
Mitchell S. Steiner F.A.C.S.,
Compensation Summary
(Year 2024)
Salary $804,049
Option Awards $516,774
Incentive Plan Pay $656,380
Total Compensation $1,977,203
Industry Biotechnology
Sector Healthcare
Went public February 11, 1999
Method of going public IPO
Full time employees 210
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-08-11 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 12
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Outperform 1
Showing Top 1 of 1
Price Target
Target High $5
Target Low $3
Target Median $4
Target Consensus $4
Institutional Ownership
BLACKROCK INC.
Shares:7.65M
Value:$18.52M
PVG ASSET MANAGEMENT CORP
Shares:1.65M
Value:$3.99M
POTOMAC CAPITAL MANAGEMENT, INC.
Shares:654K
Value:$1.58M
Summary
% Of Shares Owned 80.19%
Total Number Of Holders 84
Showing Top 3 of 84
Market Cap $37.08 M
52w High $14.20
52w Low $2.10
Dividend Yield 0.37%
Frequency Quarterly
P/E -2.26
Volume 97.37K
Outstanding Shares 16.05M
About Veru Inc.
https://www.verupharma.comVeru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.55M ▼ | $-7.33M ▲ | 0% | $-0.5 ▲ | $-8M ▲ |
| Q2-2025 | $0 | $8.12M ▼ | $-7.9M ▲ | 0% | $-0.54 ▼ | $-9.07M ▲ |
| Q1-2025 | $0 ▼ | $10.25M ▼ | $-8.95M ▼ | 0% ▲ | $-0.32 ▲ | $-10.88M ▼ |
| Q4-2024 | $6.66M ▲ | $10.89M ▼ | $-8.53M ▲ | -128.15% ▲ | $-0.58 ▲ | $-7.84M ▲ |
| Q3-2024 | $3.95M | $12.28M | $-10.97M | -277.42% | $-0.75 | $-10.61M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $15.79M ▲ | $29.84M ▲ | $11.5M ▼ | $18.33M ▲ |
| Q3-2025 | $15.01M ▼ | $27.33M ▼ | $11.99M ▲ | $15.34M ▼ |
| Q2-2025 | $20.02M ▼ | $32.67M ▼ | $11.62M ▼ | $21.05M ▼ |
| Q1-2025 | $26.61M ▲ | $39.83M ▼ | $13.2M ▼ | $26.63M ▼ |
| Q4-2024 | $24.92M | $60.42M | $28.1M | $32.32M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.33M ▲ | $-5.48M ▲ | $474.06K ▼ | $0 | $-5.01M ▲ | $-5.48M ▲ |
| Q2-2025 | $-7.9M ▲ | $-7.74M ▲ | $1.15M ▼ | $0 ▲ | $-6.59M ▼ | $-7.74M ▲ |
| Q1-2025 | $-8.95M ▼ | $-11.33M ▼ | $17.25M ▲ | $-4.22M ▼ | $1.69M ▲ | $-11.33M ▼ |
| Q4-2024 | $-8.53M ▲ | $-4.37M ▲ | $131.5K ▲ | $0 ▼ | $-4.23M ▲ | $-4.43M ▲ |
| Q3-2024 | $-10.97M | $-5.65M | $55.37K | $3.28K | $-5.59M | $-5.7M |
Revenue by Products
| Product | Q1-2021 | Q2-2023 | Q3-2023 | Q4-2023 |
|---|---|---|---|---|
 Other Products | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Preboost Segment | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2023 | Q2-2024 | Q1-2024 | Q3-2024 |
|---|---|---|---|---|
 MOZAMBIQUE | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Countries | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Geographical Areas | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 U | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| Z | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Mitchell S. Steiner F.A.C.S.,
Compensation Summary
(Year 2024)
Salary $804,049
Option Awards $516,774
Incentive Plan Pay $656,380
Total Compensation $1,977,203
Industry Biotechnology
Sector Healthcare
Went public February 11, 1999
Method of going public IPO
Full time employees 210
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-08-11 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 12
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Outperform 1
Showing Top 1 of 1
Price Target
Target High $5
Target Low $3
Target Median $4
Target Consensus $4
Institutional Ownership
BLACKROCK INC.
Shares:7.65M
Value:$18.52M
PVG ASSET MANAGEMENT CORP
Shares:1.65M
Value:$3.99M
POTOMAC CAPITAL MANAGEMENT, INC.
Shares:654K
Value:$1.58M
Summary
% Of Shares Owned 80.19%
Total Number Of Holders 84
Showing Top 3 of 84